Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA MLF2
- Development stage
- Preclinical
- Lead developer
- Methodist Hospital Research Institute
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
siRNA MLF2 is an experimental, research-stage small interfering RNA (siRNA) therapeutic designed to target and silence the myeloid leukemia factor 2 (MLF2) gene. Developed primarily by researchers at the Houston Methodist Research Institute and Weill Cornell Medicine, siRNA MLF2 works by inhibiting MLF2 expression, which has been identified as a key driver of tumor initiation, metastasis, and nitric oxide (NO) signaling pathways in triple-negative breast cancer (TNBC). In preclinical studies, siRNA MLF2, often delivered via a multistage vector (MSV) nanoparticle platform and evaluated in combination with siRNA RPL39 or chemotherapy, significantly reduced tumor volume, lung metastases, and breast cancer stem cell (BCSC) markers in patient-derived xenograft (PDX) models.
- Other names
- MLF2 siRNAMLF-2 siRNAMLF 2 siRNA
02
Targets
NOS1 (nNOS)Myeloid leukemia factor 2 mRNARibosomal protein L39 messenger RNA
Beyond the preview
Go deeper on siRNA MLF2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA MLF2.